Faeth Therapeutics, Inc. (FTH) stock forecast and price target
Price $10.03 · data as of November 13, 2026
12-month price target
Average target$56.15
Upside / downside+459.9%
Analysts13
ConsensusStrong buy
Low $40.00Average $56.15High $69.00
Gold marker: average target · white marker: today’s price ($10.03)
Analyst ratings
Strong buy 3Buy 13Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-15.60 | — | $0 |
| Next fiscal year ends December 31, 2027 | $-3.67 | +76.5% | $0 |
| Next quarter ends December 31, 2026 | $-0.88 | — | $0 |
| Quarter after ends March 31, 2027 | $-0.89 | — | $0 |
Consensus of the analysts covering Faeth Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the Faeth Therapeutics stock price target?
The average 12-month target from 13 analysts is $56.15, 459.9% above the current price of $10.03 Targets range from $40.00 to $69.00.
Is Faeth Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 13 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Faeth Therapeutics expected to earn?
Analysts expect EPS of $-15.60 for the fiscal year ending December 31, 2026 and $-3.67 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.